34,500 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by Militia Capital Management LLC

Militia Capital Management LLC purchased a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 34,500 shares of the company’s stock, valued at approximately $863,000.

Other institutional investors also recently modified their holdings of the company. Parallel Advisors LLC lifted its position in shares of PROCEPT BioRobotics by 445.3% during the 1st quarter. Parallel Advisors LLC now owns 2,950 shares of the company’s stock valued at $74,000 after acquiring an additional 2,409 shares during the last quarter. Assetmark Inc. grew its holdings in shares of PROCEPT BioRobotics by 204.9% in the 1st quarter. Assetmark Inc. now owns 24,118 shares of the company’s stock worth $603,000 after acquiring an additional 16,208 shares during the last quarter. Center for Financial Planning Inc. grew its holdings in shares of PROCEPT BioRobotics by 59.6% in the 1st quarter. Center for Financial Planning Inc. now owns 2,040 shares of the company’s stock worth $51,000 after acquiring an additional 762 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of PROCEPT BioRobotics during the first quarter worth $994,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of PROCEPT BioRobotics during the first quarter worth $8,495,000. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $17.55 on Friday. The firm has a 50 day simple moving average of $23.53 and a 200 day simple moving average of $25.81. PROCEPT BioRobotics Corporation has a 52 week low of $17.17 and a 52 week high of $60.57. The stock has a market cap of $998.95 million, a P/E ratio of -9.64 and a beta of 0.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The company had revenue of $83.13 million during the quarter, compared to analyst estimates of $80.52 million. During the same quarter in the prior year, the company posted ($0.45) EPS. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. Research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PRCT shares. Evercore started coverage on PROCEPT BioRobotics in a report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 target price for the company. Truist Financial restated a “hold” rating and set a $25.00 price objective (down from $30.00) on shares of PROCEPT BioRobotics in a report on Thursday, July 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $37.27.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.